| Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. | |
| | |
MedLine Citation:
|
PMID: 20014944 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted. |
| | |
Authors:
|
Pratima Kamada; Arkadiusz Z Dudek |
Related Documents
:
|
16049384 - Clinical and morphological diagnosis of cardiac al amyloidosis: a review of findings an... 18765314 - Cardiac involvement with lymphoma: a review of the literature. 15680004 - Long on qt and low on calcium. 2260584 - Incidence of tuberous sclerosis in patients with cardiac rhabdomyoma. 19643644 - Urinary tract infection as a single presenting sign of multiple vaginal foreign bodies:... 6854144 - Leiomyoma of the palate. |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Cancer investigation Volume: 28 ISSN: 1532-4192 ISO Abbreviation: Cancer Invest. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-10 Completed Date: 2010-05-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307154 Medline TA: Cancer Invest Country: England |
Other Details:
|
Languages: eng Pagination: 501-4 Citation Subset: IM |
Affiliation:
|
Department of Oncology, and Transplantation, University of Minnesota, Minneapolis, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents / adverse effects* Benzenesulfonates / adverse effects* Carcinoma, Renal Cell / complications*, drug therapy*, pathology Female Heart Diseases / complications*, physiopathology Humans Kidney Neoplasms / complications*, drug therapy*, pathology Male Middle Aged Neoplasm Metastasis Pyridines / adverse effects* Stroke Volume* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Benzenesulfonates; 0/Pyridines; 0/sorafenib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of WISP3 and RhoC Genes at mRNA and Protein Levels in Inflammatory and Noninflammatory Br...
Next Document: Correlation Between Argyrophilic Nucleolar Organizer Region Staining and Brain Tumor Classification ...